Source: PharmiWeb

Vybion: Vybion Receives Orphan Drug Designation for INT41 in Huntington's Disease

Vybion Receives Orphan Drug Designation for INT41 in Huntington's DiseaseVybion Inc....Vybion Inc.

Read full article »
Vybion's Competitors | Vybion's News | Vybion's Financials
Stay up-to-date with the latest news on Vybion
Est. Annual Revenue
$5.0-25M
Est. Employees
100-250
CEO Avatar

CEO

Update CEO

CEO Approval Rating

- -/100

Read more
Stay up-to-date with the latest news on Vybion